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Abstract 
Technological advances enabling us to personalise medical interventions at the biological level must be 
matched by parallel advances in how we support the informed choices essential to patient and public 
participation. We cannot take participation for granted. To be truly personalised, medicine must take 
account of the perceptions and capabilities that shape participation. To do this, we need a better 
understanding of how people perceive personalised medicine and how they judge its value and risks. To 
realise the promise of personalised medicine 4P medicine we need to personalise at the psychosocial as 
well as biological dimension, putting the person personalised medicine.  
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Introduction 
The idea of personalising treatment is at the core of medicine and can be traced back to the teachings of 
Hippocrates(Sykiotis et al., 2005). Hippocrates’ therapeutic strategy was based on understanding the 
idiosyncrasia - the unique characteristics of the individual determining response to the disease and 
treatment. Identifying the patient’s idiosyncrasia enables tailored treatment by ‘making changes in 
drugging or in regiment to suit the several conditions of age, season, physique and disease’(Jones, 1931, 
Sykiotis et al., 2005). In recent years, the concept of personalised (or stratified) medicine has been 
reinvigorated by scientific advances in genomics promising treatment approaches tailored to the genetic 
characteristics of the individual(Horne et al., In Preparation).  
Taken together, advances in genomics, data-analytics and e-health technologies offer the prospect of 4P 
Medicine that is predictive, pre-emptive, personalised and participatory(Horne and Hankins, In 
Submission). We are now able to characterise Hippocrates’ idiosyncrasia more accurately than ever 
before. With this, 4P medicine promises to take us beyond the one size fits all, population-based 
strategy that has produced the ‘blockbuster drugs’ of the past, to tackle the rising tide of chronic disease 
in ageing populations and re-orientate health services from a focus on treating established diseases 
(often when it is too late) to the maintenance of health. 
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The ghost in the machine: extending personalisation to include 
psychosocial aspects of the person 
Participation is at the centre of the 4P model, and rightly so (see Figure 1). But how will this work in 
practice?  
 
Insert fig 1 here  
 
It is often assumed that widespread access to medical data, diagnostic tests and health maintenance 
apps, coupled with the democratization of medical knowledge, will empower individuals to self-manage 
health and illness. However, this level of participation is unlikely to occur if left to chance on the 
assumption that it will emerge as a corollary of the scientific evidence supporting biomedical 
personalization (Horne et al., 2015).  
To make 4P work we need to extend our focus beyond the biological and technological to take account 
of the psychosocial factors that make us unique and influence health behaviours and outcomes. In 
recognition of this principle, Gorini and Pravettoni have called  for the addition of a fifth ‘P’  (psycho-
cognitive) to the 4P model to increase its feasibility(Gorini et al., 2008). To be truly personalised (and 
hence, more effective) treatment must address two aspect of personalisation: biological and 
psychosocial. 
Potential disconnects between the person and personalised medicine   
Consider an imagined outcome of 4P shown in Box 1. Although exaggerated, this characterisation 
provides a frame for discussing some of the psychosocial challenges to 4P medicine and how these 
might be addressed by connecting biomedical and psychosocial aspects of personalisation. The key issue 
is the encounter of the individual with the specific healthcare service or treatment. In Winston’s case, 
we are looking at the interaction of the person with personalised medicine.  
Box 1 – Characterisation of 4P medicine 
Winston Orwell has just returned from his daily 10Km run. Scrutinizing his svelte 70Kg 
form in front of his interactive bathroom mirror, he asks BioSys (affectionately known 
as Big Sister) to activate his health check screen. The info graphic shows that his health 
profile indices are all in the green zone. Prometheus, his medication monitor, reminds 
him that his daily dose of Tailoran is due. He pops the pill and reflects on taking 
Tailoran for 40 years since it was prescribed in response to his genetic risk, tailored to 
his pharmacodynamic and pharmacokinetic profile. Winston is 98 years old.  
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When healthcare is made available to the individual, engagement is essentially determined by a, 
sometimes complex, interplay between motivation and ability. There are a number of potential 
disconnects between the person and personalised medicine which might reduce motivation and/or 
ability to participate in 4P medicine.  
 
Motivation to participate: the importance of public perceptions of value and risk 
We see from Winston’s morning encounter with Bio Sys an active routine engagement with health 
maintenance requiring daily monitoring, exercise and taking Tailoran, a preventative medication. The 
scenario implies that they have become a regular healthy habit, so we assume that Winston’s economic 
circumstances allow the time and space to perform these tasks. This assumption highlights a challenge 
to realising the promise of 4P medicine: the question of equality of access. A full discussion is beyond 
the scope of this paper though the issue is dealt with in more detail elsewhere(Barker, 2016). However, 
if we think back to the personal level and the question of participation, we see that although Winston’s 
health maintenance behaviours have become routine, establishing the routine would have required 
motivation. Can we assume that the motivation to participate in the predictive and pre-emptive health 
maintenance envisioned by 4P medicine will be an automatic corollary of the technological capability? 
Based on the evidence for public engagement in current preventative health measures the answer is 
‘probably not’.  
As with most innovations there will be early enthusiastic adopters but others may need more 
convincing. What might this entail? Simply presenting Winston with the evidence for the benefits of 
prevention and the risks of doing nothing may not be enough. The idea that health-related behaviour 
arises from rational choices based on objective assessments of the evidence is challenged by research in 
behavioural economics that choices are influenced by an array of psychological and environmental 
factors, including systematic biases in how we interpret and value information or evidence (Kahneman, 
2011, Tversky and Kahneman, 1985).  
Technological advances enabling us to personalise medical interventions at the biological level must be 
matched by parallel advances in how we support the informed choices essential to patient and public 
participation. We cannot take participation for granted. To be truly personalised, medicine must take 
account of the perceptions and capabilities that shape participation. To do this, we need a better 
understanding of how people perceive personalised medicine and how they judge its value and risks. 
 
Prevention is better than cure but less motivating  
For many health as value is defined more by its absence than presence(Lau et al., 1986). For many, when 
they feel well, matters of health and illness tend to recede into the background. Our attention is focused 
on health more when we become ill or when we fear losing it. This may be a poor spring board for 
participation in 4P medicine where targeted pre-emption is predicated on early action that is 
presumably sustained over the long-term.  
The ability to predict future disease is core to 4P medicine and is becoming a reality. But little is known 
about whether people will want this information or how it might influence behaviour and well-being. Do 
people want to know their genetic risk and will knowledge of risk be sufficient to motivate the 
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behaviours necessary to mitigate the risk? Effects of risk information on behaviour may be paradoxical 
and influenced by erroneous beliefs about disease and treatment. There is a common perception that 
genetic risk is immutable and this might weaken beliefs in the efficacy of intervention and reduce the 
motivation to adopt preventative behaviours(Marteau and Lerman, 2001). However, little is known 
about public perceptions of the genetic risk information that underpins pre-emption in 4P medicine or 
the public’s willingness to engage in the privative necessary to avoid them. 
 
Nonadherence to treatment: the importance of common-sense evaluations of illness and 
treatment  
The World Health Organisation has estimated that about half of medicines prescribed for long term 
conditions are not taken as advised(Sabaté, 2003). There are many, complex reasons for this but as with 
most other behaviours adherence is a product of motivation, capability and opportunity. To understand 
why a person might follow a treatment recommendation over the long-term, we need to understand 
the perceptions that underpin motivation as well as the practicalities that determine access and ability 
to adhere. There is, of course, a degree of overlap between these factors: we may be more motivated to 
do something that is easy and accessible being motivation might help us to overcome certain barrier 
.s.However, studies of adherence have consistently shown that nonadherence is often related to 
peoples’ personal beliefs about illness and treatment, which may be at odds with the medical view or 
scientific evidence(Horne et al., 2005).  
A recent systematic review and meta-analysis showed that providing information about the benefits and 
harms of medication had no overall impact on decisions about whether to start and continue medicines, 
although it increased knowledge and make people feel more comfortable about their decision(Crockett 
et al., 2011). One reason for this finding is that decisions about medicines are not influenced by the 
scientific evidence alone but also by the beliefs and values that the person brings to the encounter with 
the prescription(Horne et al., 1999, Horne and Weinman, 1999).  
 
Making decisions about taking medicines: The Necessity Concerns Framework  
Studies of adherence to prescribed medicines consistently link that nonadherence to patients’ beliefs 
andin particular, the way in which the individual judges their personal need for the medicine (necessity 
beliefs) relative to their concerns about taking it.(Horne et al., 2013) 
Necessity beliefs might be thought of as the answer to two questions: ‘How much do I need this 
treatment to achieve a goal that’s important to me?’ and ‘How much can I get away without it?’. We ask 
the latter question because pharmaceuticals are commonly perceived as a ’double-edged sword’ where 
therapeutic efficacy goes hand in hand with the potential for harm(Horne et al., 1999, Horne, 1999). This 
representation might be traced back to the Ancient Greeks who had one word for medicine and poison: 
pharmakon, the origin of ‘pharmaceutical’. It may also stem from a more basic aversion to taking regular 
medication(Pound et al., 2005), or even to the meaning we attach to taking regular treatments and its 
impact on our sense of self or how we think others see us(Cooper et al., 2002). Perceived necessity is 
not a form of efficacy belief: we might believe that a treatment will be effective but not that we need it. 
We might have a low necessity belief even if we understand the scientific evidence for the potential 
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benefits of treatment. This might occur because we do not ‘value’ that particular benefit or perceive it 
be important enough to overcome our concerns about taking the medicine.  
We might question how Winston is convinced of his personal need to take Tailoran for 40 years. Most 
people do not blindly follow treatment advice. Rather, we evaluate the value of the advice and make a 
judgement on whether we need to follow it. This applies even when we trust the doctor. A nonadherent 
patient might trust the doctor but not the prescription. Evaluations of personal need for the treatment 
are influenced by common-sense understanding of the condition for which the treatment is prescribed. 
To be convinced of a personal need for ongoing medication, we must first perceive a good fit between 
our conception of the problem (the illness or condition) and the solution (the medicine) (Horne and 
Weinman, 2002). Here, symptom perceptions relative to expectations are key(Horne and Weinman, 
2002).  The treatment proposition may be more convincing when we experience symptoms that we 
perceive to be relieved by the medicine than if we are taking the medicine to prevent a condition from 
arising(Cooper et al., 2009).  
Before we are diagnosed with a chronic illness, most of our experience of illness is symptomatic and 
acute. However, for many long-term conditions, and presumably many of the pre-emptive treatments in 
4P medicine, the medical rationale for treatment is based on a prophylaxis model where the benefits of 
treatment are often ‘silent’ and realised in the long-term. This may be in stark contrast to our intuitive 
model of ‘no symptoms; no problem’(Halm et al., 2006). Similarly, missing doses may not lead to an 
immediate deterioration in symptoms, reinforcing the erroneous perception that high adherence to the 
medication may not be necessary. Related to this is the fact that people often stop taking treatment 
when they judge that the condition has improved, usually if symptoms ameliorate.  
Information about the potential benefits of treatment may be less persuasive than ‘concrete’ symptom 
experiences. This is illustrated by a study exploring the reasons why people decided not to take a 
clinically indicated offer of antiretroviral treatment (ART) for HIV infection. Evidence-based guidelines 
for the optimum time to initiate ART stipulate CD4 count (an indicator of immune status) and viral load 
(a marker for disease activity) as key indicators for when ART is clinically indicated. However, receiving 
‘abstract’ information about personal CD4 and viral load lab results was less persuasive than more 
‘concrete’ symptom experiences. A common reason given by interviewees for refusing ART was that 
they were experiencing few, if any, of the symptoms that they associated with HIV-infection. Their 
common-sense interpretation of their experiences (feeling fine) seemed to convince them that they did 
not need treatment yet and could afford to delay starting ART, despite the scientific evidence supporting 
an immediate start.(Horne et al., 2007)   
Concerns about medication There is a striking similarity in the type of concerns that patients report 
about prescription medicines. One obvious source of concern is the experience of symptoms as 
medication ‘side-effects’ and the disruptive effects of medication on daily living; but this is not the 
whole picture (Cooper et al., 2015). Many patients receiving regular medication who have not 
experienced adverse effects are still worried about possible problems in the future. These concerns 
often arise from the belief that regular use can lead to dependence or that the medication will 
accumulate within the body and lead to long-term effects(Horne and Weinman, 2002). Concerns also 
relate to the meaning that being on regular medication has for the individual and their sense of 
self(Cooper et al., 2002). Concerns about specific medicines are also related to more general beliefs 
about pharmaceuticals as a class of treatment. Many people seem to have a fairly negative orientation 
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to pharmaceuticals, perceiving them to be fundamentally harmful, addictive substance that should not 
be taken for long periods of time but that tend to be over-prescribed by doctors(Horne et al., 1999). 
Moreover, the dangerous aspects of medication are often linked to their chemical/unnatural origins and 
to suspicions of the pharmaceutical industry and scientific medicine (Horne et al., 1999) (Britten et al., 
2010, Pound et al., 2005). In experimental studies, people with more negative views about 
pharmaceuticals in general  are more likely to think that symptoms are caused by a specific drug 
(attribute symptoms as side-effects)(Heller et al., 2015) and less likely to recall side effects 
correctly.(Heller et al., in press) 
 
Public perceptions of personalised medicine  
The adherence literature points to the existence of a profound disconnect between a deterministic view 
of treatment based on scientific medicine and the ‘common-sense’ evaluations of illness and treatment 
of many patients. But are these issues likely to be relevant for personalised medicine which, promises to 
be more effective and less harmful; because it is targeted to the biological characteristics of the 
individual? To answer this question, we need more research into patient and public perceptions and 
behaviour in relation to personalised medicine. But the early indicators are that biological 
personalisation may not guarantee behavioural participation.  
Consider two illustrative examples. First,the anticancer drug Imatinib is an example of a personalised 
medicine, prescribed for patients with Philadelphia chromosome positive chronic myeloid 
leukaemia(Issa, 2007). In a study of adherence to Imatinib, Marin and colleagues found that 26% of 
patients were nonadherent with nonadherence as the only predictor of poor clinical response to the 
drug(Marin et al., 2010). This study did not assess the reasons for nonadherence but in a separate 
interview-based study patients nonadherence to Imatinib was associated with patients beliefs(Eliasson 
et al., 2011). A second indicator that participation may not be an automatic corollary of personalised 
medicine was provided by an analogue study of public attitudes to hypothetical treatments for glandular 
fever. A medicine personalised to the genetic profile of the individual was perceived as no more 
effective and no less harmful than a pharmaceutical medicine and significantly less harmful than a 
natural remedy(Green et al., 2013).   
 
The problem of the ‘B’ Patient 
A further issue arises in relation to ‘molecularly unstratified’ or ‘B’ patients. Personalised medicine (PM) 
involves tailoring medical treatment based on the individual’s biological data. Implicit in the notion of 
targeting a treatment to a particular genetic profile is that the process of tailoring will identify patients 
who do not have the genetic profile that fits the drug: a ‘B’ Patient. When the drug offers the potential 
to stay the course of an otherwise fatal condition, how we do we ameliorate the consequences of 
informing a ‘B’ patientthat they are not eligible for the treatment? In parallel with the development of 
technological aspects of biological personalisation, we require equally innovative approaches to the 
management of patients who are not eligible for genetically targeted treatments, including how we 
might ameliorate the psychological effects of being in the B stream for life-saving treatments. The need 
for humane end of life care that is tuned to psychological and spiritual needs will remain even in the era 
of 4P medicine (see Hordern this volume for a more detailed discussion).  
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Conclusions 
In conclusion, biomedical advances, although fundamental, cannot deliver on the promise of 
personalised medicine in isolation. We now have the capacity to characterise Hippocates idiosyncrasia 
more accurately from the biological perspective, than ever before. But the promise of personalised 
medicine will only be fully realised if we develop better methods for characterising the psychosocial 
idiosyncrasia influencing engagement and outcome. Good prescribing is about the application of 
psychology as well as pharmacology.  
We should tailor the prescription to take account of the patients’ beliefs and preferences. This is 
essential if we are to support informed treatment choices. Informing should be an active process, which 
involves more than simply presenting the evidence. It also entails eliciting the patient’s beliefs and 
identifying whether pre-existing beliefs might act as a barrier to an unbiased interpretation of the 
evidence. If the interpretation of information is influenced by misconceptions about the illness and 
treatment, then can the choice be truly informed?(Horne, 2006) Addressing psychosocial aspects of the 
patients encounter with the treatment might also have direct effects of outcome by enhancing the 
nonspecific beneficial effects (‘placebo’ component) and reducing the non-specific harmful effects 
(‘nocebo’ component) of pharmacologically active treatments(Rief et al., 2011).  Although these 
approaches are in their infancy, personalising information about medicines to take account of individual 
patients’ doubts and concerns can be achieved in brief and cost-efficient interventions that improve 
engagement with essential treatments (Clifford et al., 2006, Elliott et al., 2008, Petrie et al., 2012). To 
realise the promise of personalised medicine 4P medicine we need to personalise at the psychosocial as 
well as biological dimension, putting the person personalised medicine.  
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